Antithrombotic Nanoparticle Localized PPACK Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticoagulant therapies for preventing blood clots are often ineffective in preventing unpredictable thrombus formation and can lead to severe bleeding complications due to systemic effects, highlighting a need for safer and more targeted antithrombotic solutions.
Innovation Solution
Development of antithrombotic nanoparticles with a high affinity coagulation inhibitor, such as PPACK, that are specifically designed to be retained on the nanoparticle surface, providing localized anticoagulant activity without significantly altering blood plasma clotting time, and having a half-life of 2-4 hours for targeted thrombus inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemically active anticoagulants are administered to prevent clot progression, then thrombus formation is inhibited, but severe or fatal bleeding problems arise
Solution Approach 1:
The patent applies local quality by concentrating the anticoagulant effect specifically at the thrombus site through nanoparticle accumulation. The nanoparticles deliver coagulation inhibitors directly to the clot location, creating a localized high concentration of antithrombotic activity while maintaining normal systemic coagulation parameters, thereby preventing bleeding complications that occur with systemic anticoagulant therapy
Solution Approach 2:
The nanoparticle serves as an intermediary carrier that delivers coagulation inhibitors to the thrombus site. This intermediary approach allows the inhibitor to reach the target location with high specificity, mediating the antithrombotic effect locally without requiring systemic circulation of free anticoagulants that cause bleeding risks
2Reliability
If high affinity coagulation inhibitors are used to prevent thrombus formation, then clotting is inhibited, but unpredictable thrombus formation still proceeds
Solution Approach 1:
The patent applies preliminary action by pre-loading nanoparticles with coagulation inhibitors before administration. The nanoparticles are prepared in advance with high concentrations of inhibitors on their surface, enabling them to immediately neutralize thrombin and other coagulation factors upon reaching the thrombus site, providing predictable and reliable prevention of clot progression
Solution Approach 2:
The nanoparticle provides continuous antithrombotic action by maintaining a sustained reservoir of coagulation inhibitors at the thrombus site. The nanoparticle slowly releases or presents inhibitors over time, ensuring continuous inhibition of thrombin generation and clot propagation, making the antithrombotic effect more predictable and reliable
3Reliability
If coagulation inhibitors are administered systemically, then thrombus formation is prevented, but the clotting time of blood plasma is substantially altered
Solution Approach 1:
The nanoparticle creates a local quality difference between the thrombus site and the rest of the circulation. At the thrombus site, high concentrations of coagulation inhibitors are present on the nanoparticle surface, providing effective thrombus prevention. In the systemic circulation, the nanoparticle remains intact with inhibitors bound to its surface, preventing free inhibitor circulation that would alter plasma clotting time
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles effectively delay thrombus formation and minimize systemic bleeding risks by maintaining localized anticoagulant activity, with PPACK nanoparticles demonstrating a prolonged therapeutic effect and enhanced antithrombin activity compared to free PPACK, while maintaining normal systemic coagulation times.
Implementation Method 1
the exterior of the nanoparticle comprises at least one high affinity coagulation inhibitor that is substantially retained on the exterior of the nanoparticle after administration of the nanoparticle to a subject
Data Source
AI summary
The present invention encompasses an antithrombotic nanoparticle and use thereof.